{"filings":[{"id":14001,"accession_number":"0001628280-26-033580","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2026-05-11T20:34:04+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS FY26 revenue $5.9B (+9%), adj EPS $10.17; FY27 guidance adj EPS $11.10-$11.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year revenue from continuing ops $5.9B (+9%), constant currency organic +7%; adjusted EPS $10.17 vs $9.22.","Q4 revenue $1.6B (+7%), adjusted EPS $2.83 vs $2.74; Healthcare rev $1.14B (+7%), AST $289.2M (+6%), Life Sci $162.9M (+9%).","FY26 operating cash flow $1.34B, free cash flow $982.9M (up from $787.2M).","FY27 guidance: revenue +7-8%, organic +6-7%, adj EPS $11.10-$11.30 (9-11% growth), capex ~$375M, FCF ~$850M.","Board authorized new $1B share repurchase program; $60M strategic investment for new sterility plant in Mentor, Ohio (operational late CY2027)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95231,"accession_number":"0001193125-26-212159","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"STERIS appoints Pierre Boulud to board; Richard Breeden to retire at 2026 AGM","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard C. Breeden notified he will not stand for reelection at 2026 AGM; retirement not due to any disagreement.","Board increased from 9 to 10 members; Pierre Boulud appointed director effective May 5, 2026.","Boulud is CEO of bioMérieux (in vitro diagnostics); previously COO at bioMérieux and exec at Ipsen.","Boulud receives prorated fee of $76,989 in restricted stock units for remainder of board term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95230,"accession_number":"0001193125-26-143973","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"STERIS extends former CFO Tokich's advisory role through March 2027 with reduced pay","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Tokich's senior financial advisor role extended part-time from April 1, 2026 to March 31, 2027.","Annual base salary reduced to $60,000 during the Extended Advisor Period.","Tokich eligible for discretionary cash bonus subject to CEO and Compensation Committee approval.","Tokich will lose health, dental, life insurance, vacation, disability, and other employee benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108138,"accession_number":"0001628280-26-005473","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q3 revenue +9% to $1.5B; adj EPS $2.53 beats prior year $2.32; FY2026 outlook maintained","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.5B (+9% YoY); constant currency organic revenue growth 8%.","Reported EPS from cont ops $1.96; adjusted EPS $2.53 vs $2.32 last year.","Healthcare revenue $1.1B (+9%), AST $286.6M (+11%), Life Sciences $145.8M (+7%).","Free cash flow first 9 months $737.6M vs $588.1M prior year period.","FY2026 adj EPS guidance reaffirmed $10.15-10.30; tariff headwind increased to ~$55M."],"consensus_eps_estimate":null,"consensus_eps_actual":5.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":4347500000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124560,"accession_number":"0001757898-25-000011","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q2 FY2026 revenue up 10% to $1.5B; adjusted EPS $2.47; raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1.5B (+10% YoY); constant currency organic revenue +9%.","As-reported EPS $1.94; adjusted EPS $2.47 versus $2.14 last year.","Healthcare revenue +9%, AST +10%, Life Sciences +13% (all as reported).","FY2026 adjusted EPS guidance raised to $10.15-$10.30 (prior $9.90-$10.15).","Free cash flow outlook increased to ~$850M; tariff impact unchanged at ~$45M pretax."],"consensus_eps_estimate":null,"consensus_eps_actual":3.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":2851400000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141243,"accession_number":"0001757898-25-000007","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","5.02","5.07","9.01"],"status":"ready","headline":"STERIS Q1 adj EPS $2.34 vs $2.03; revenue +9%; FY revenue guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1.4B (+9% as reported, +8% organic constant currency); adj EPS $2.34 vs $2.03.","FY2026 revenue growth guidance raised to 8-9% from 6-7% on FX; adj EPS unchanged $9.90-$10.15; FCF guidance raised to ~$820M.","CFO Michael Tokich resigns effective Aug 18; CAO Karen Burton appointed CFO.","FY2026 tariff headwind estimated at $45M pretax (up from $30M).","Board changes: Louis Shapiro elected; Dr. Kosecoff and Dr. Steeves retired."],"consensus_eps_estimate":2.8767,"consensus_eps_actual":1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":1391100000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141242,"accession_number":"0001193125-25-155509","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"STERIS director Richard Steeves to retire from board at July 31 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Richard Steeves notified STERIS of retirement effective at July 31, 2025 Annual General Meeting.","Steeves will not stand for re-election; decision not due to any disagreement with the Company.","Steeves served as a director for 10 years; thanked by the Company and Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159039,"accession_number":"0001757898-25-000004","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS reports fiscal 2025 adjusted EPS $9.22, revenue $5.5B; guides FY2026 EPS $9.90-$10.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year revenue from continuing ops +6% to $5.5B; constant currency organic growth 6%.","Adjusted diluted EPS $9.22 vs $8.20 prior year; as-reported EPS $6.16.","Q4 adjusted EPS $2.74 vs $2.41; revenue $1.5B (+4% as reported, +6% constant currency organic).","Healthcare revenue +5% (service +13%); AST +9% constant currency organic; Life Sciences flat organic.","FY2026 guidance: revenue +6-7%, adjusted EPS $9.90-$10.15; tariffs to reduce pre-tax profit ~$30M."],"consensus_eps_estimate":2.5578,"consensus_eps_actual":6.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":5459515000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177486,"accession_number":"0001193125-25-044247","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"STERIS subsidiary Isomedix settles EO personal injury claims for up to $48.15M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Up to $48.15M settlement for substantially all pending EO injury claims in Cook County, IL.","No admission of liability; walkaway rights if conditions not met.","$48.15M charge recorded in FY2025 (ending March 31, 2025), excluded from adjusted earnings.","Settlement funded with cash and revolver borrowings; claims administration process up to 10 months.","Isomedix anticipates dismissal of all covered EO claims upon administration completion and court approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177485,"accession_number":"0001757898-25-000001","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q3 EPS $2.32 (+11% YoY); revenue $1.4B (+6%); guidance trimmed on currency","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted EPS of $2.32 vs $2.09 YoY; GAAP EPS $1.75 vs $1.49; revenue $1.4B (+6% as reported, +6% organic constant currency)","Healthcare revenue $976M (+7%); consumables +9%, service +13%, capital equipment -5%","AST revenue $258.1M (+10%); Life Sciences -7% to $136.4M on CECS divestiture and lower capital equipment","Fiscal 2025 outlook: revenue growth ~6% (prior 6.5-7.5%), adjusted EPS $9.05-$9.15 (from $9.05-$9.25), currency headwind ~$0.10","Nine-month free cash flow $588.1M vs $457.0M YoY; capex expected ~$360M"],"consensus_eps_estimate":2.3743,"consensus_eps_actual":4.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":3978984000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194213,"accession_number":"0001757898-24-000017","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q2 adjusted EPS $2.14, revenue $1.3B (+7%); reiterates FY2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted EPS from continuing operations $2.14 vs $1.86 prior year; as-reported EPS $1.51 vs $1.20.","Total revenue $1.3B, +7% as reported and constant currency organic growth.","Healthcare revenue +9% to $944.2M, driven by consumables (+12%) and service (+14%); capital equipment -2%.","AST revenue +9% to $256.7M; Life Sciences revenue -4% to $127.9M due to divestiture, organic +3%.","FY2025 outlook reiterated: revenue growth 6.5-7.5%, adjusted EPS $9.05-$9.25, free cash flow ~$700M."],"consensus_eps_estimate":2.2861,"consensus_eps_actual":2.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":2608414000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194212,"accession_number":"0001193125-24-233855","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"STERIS enters new $1.1B revolver, replaces 2021 credit facility, matures Oct 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.1B revolving credit facility replaces the March 2021 credit agreement; proceeds for general corporate purposes.","Facility matures October 7, 2029; includes an accordion feature allowing up to $625M additional commitments.","Pricing based on STERIS debt ratings: Term Benchmark/RFR margin ranges from 0.910% to 1.425%; facility fee 0.090% to 0.200%.","Swingline subfacility and letter of credit sublimits included; Alternative Currency sublimit of $625M.","Joint lead arrangers: JPMorgan, BofA, Citibank, PNC, Wells Fargo; administrative agent: JPMorgan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210540,"accession_number":"0001757898-24-000014","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q1 FY2025 revenue $1.3B (+8%), adjusted EPS $2.03; guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue from continuing ops $1.3B, up 8% YoY; constant currency organic revenue up 6%.","As-reported EPS $1.41 (from $1.31), adjusted EPS $2.03 (from $1.84).","Healthcare revenue +10% to $901.2M; AST +7% to $249.8M; Life Sciences -2% to $128.5M due to CECS divestiture.","Segment operating income all up: Healthcare $216.9M, AST $117.7M, Life Sciences $52.6M.","FY2025 guidance reaffirmed: rev growth 6.5-7.5%, adjusted EPS $9.05-$9.25, free cash flow ~$700M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":1279502000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210539,"accession_number":"0001193125-24-191556","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"STERIS reports 2024 AGM results; all director nominees elected, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 93.55% (92.5M of 98.9M shares) present at August 1, 2024 AGM.","All 10 director nominees elected; highest votes against for Mohsen Sohi (7.07M) and Cynthia Feldmann (6.83M).","Say-on-pay advisory vote approved with ~82.3M for, ~6.5M against, and 3.65M broker non-votes.","Ratification of EY as auditor for FY2025 approved with ~83.0M for, ~9.5M against.","Shareholders approved renewal of authority to issue shares and opt-out of pre-emption rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228866,"accession_number":"0001193125-24-151805","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"STERIS closes sale of Dental business to HuFriedy Group for $787.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction closed on May 31, 2024; base purchase price $787.5M plus up to $12.5M contingent payment.","Proceeds primarily to be used to repay debt.","Contingent payment payable if Dental business achieves certain revenue targets in fiscal year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228865,"accession_number":"0001757898-24-000005","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"STERIS reports FY2024 revenue up 12% to $5.5B; GAAP EPS $3.81, adjusted EPS $8.83; announces $100M restructuring plan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.5B (+10% YoY); Q4 GAAP net loss $1.4M (-$0.01/sh) vs $187.2M profit in prior year.","Full-year adjusted EPS grew to $8.83; constant currency organic revenue from cont. ops +10% to $5.0B.","Restructuring plan: ~$100M total charges, $44.4M recorded in Q4, balance in FY2025; $50M non-cash, $37M employee termination, $13M other.","Healthcare segment outperformed driven by US strength; CEO cites confidence in long-term growth commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":3.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":5138701000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228864,"accession_number":"0001193125-24-092481","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"STERIS to sell Dental segment to Peak Rock Capital for $787.5M cash, plus earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $787.5M cash (subject to adjustments) plus up to $12.5M earnout on FY2025 revenue targets.","Dental segment reported $407M revenue and $86M segment operating income in trailing 12 months ended Dec 31, 2023.","Transaction expected to close in Q1 FY2025; proceeds primarily to repay debt, with estimated interest expense benefit of ~$0.35/sh.","Segment to be reported as discontinued operations for Q4 and full year FY2024; FY2025 outlook to be provided with Q4 results.","Closing subject to Hart-Scott-Rodino approval and customary conditions; termination fee of $35M payable by buyer in certain scenarios."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247506,"accession_number":"0001757898-24-000001","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q3 revenue rises 15% to $1.40B, adjusted EPS $2.22, outlook updated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.40B, +15% as reported; constant currency organic revenue +10%.","Diluted EPS as reported $1.42; adjusted EPS $2.22.","Fiscal 2024 outlook updated; no specific guidance figures provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":3.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":4022547000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264968,"accession_number":"0001757898-23-000012","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS reports Q2 FY2024 revenue $1.34B, up 12%; EPS $1.16, adjusted $2.03","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $1.34B increased 12% as reported and 8% constant currency organic from $1.20B in Q2 FY2023.","GAAP diluted EPS $1.16; adjusted diluted EPS $2.03 for the quarter ended Sept 30, 2023.","Fiscal 2024 outlook maintained; no update to prior guidance provided.","Constant currency organic revenue growth of 8% highlights underlying demand strength."],"consensus_eps_estimate":null,"consensus_eps_actual":2.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":2626902000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264967,"accession_number":"0001193125-23-272446","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K/A","filed_at":"2023-11-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"STERIS board adopts annual say-on-pay frequency per shareholder advisory vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding shareholder vote at July 27, 2023 AGM favored annual say-on-pay frequency.","Board determined to hold advisory say-on-pay votes annually until next required frequency vote or board decision otherwise.","Determination aligns with board's prior recommendation in the June 7, 2023 proxy statement.","No other changes to the original July 27, 2023 Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282157,"accession_number":"0001757898-23-000008","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q1 revenue $1.28B (+11% YoY), adj. EPS $2.00, GAAP EPS $1.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $1.28B, up 11% as reported and constant currency organic.","As reported diluted EPS $1.25; adjusted diluted EPS $2.00.","Fiscal 2024 outlook updated to reflect acquisition of BD surgical instrumentation assets (no financial details provided).","Constant currency organic revenue growth drove the quarter, with all segments contributing."],"consensus_eps_estimate":null,"consensus_eps_actual":1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":1284542000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282156,"accession_number":"0001193125-23-196145","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"STERIS plc reports results of 2023 Annual General Meeting; all proposals passed","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 91.7M shares (92.97% of outstanding) present at the July 27, 2023 meeting.","All 10 director nominees elected; Cynthia L. Feldmann received 5,944,870 votes against but still elected.","Ratification of Ernst & Young as auditor for FY2024 passed with 83,026,435 for, 8,633,905 against.","Non-binding advisory vote on executive compensation passed with 81,238,272 for (~92% of votes cast).","One-year frequency for say-on-pay approved with 87,154,402 votes (98.9% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282155,"accession_number":"0001193125-23-196154","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K/A","filed_at":"2023-07-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"STERIS appoints Dr. Esther Alegria to board committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Alegria appointed to Compliance and Technology Committee and Nominating and Governance Committee effective July 27, 2023.","Board had previously elected Dr. Alegria as director on May 3, 2023.","This amendment to 8-K adds only initial committee assignments; no other changes from original filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301267,"accession_number":"0001193125-23-169645","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"STERIS acquires surgical instrumentation assets from BD for $540M; expects close by Sept 30, 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $540M in cash; assets include V. Mueller, Snowden-Pencer, Genesis brands.","Annual revenue for acquired businesses ~$170M; adjusted EBIT ~$45M (fiscal 2023 projected).","Expected to close by Sept 30, 2023, subject to HSR and customary conditions.","Deal financed via debt and cash on hand; expected accretive to adjusted EPS in FY2024.","STERIS anticipates ~$60M present value tax benefit from goodwill."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301266,"accession_number":"0001757898-23-000004","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS reports Q4 revenue $1.38B (+14%), adjusted EPS $2.30; FY2024 outlook provided","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.38B, up 14% YoY; constant currency organic revenue growth 16%.","Q4 as reported EPS $1.88; adjusted EPS $2.30.","Fiscal 2024 outlook provided in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":4957839000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301265,"accession_number":"0001193125-23-134570","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"STERIS appoints Esther Alegria to Board of Directors effective May 3, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to ten members; Dr. Alegria, age 64, appointed immediately.","She is Founder & CEO of APIE Therapeutics; previously SVP Global Manufacturing at Biogen.","Prorated director fee of $74,220 payable in restricted stock units for remainder of 2022-23 term.","Also serves on AVID Bioservices (NASDAQ: CDMO) board and its audit and governance committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321120,"accession_number":"0001757898-23-000001","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q3: Revenue $1.22B (+1% as reported, 7% constant currency organic), adj EPS $2.02","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.22B, up 1% as reported; constant currency organic revenue growth 7%.","As reported EPS $1.24; adjusted EPS $2.02.","Updated fiscal 2023 outlook provided in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":3573002000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339223,"accession_number":"0001757898-22-000020","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS reports flat Q2 revenue, adjusted EPS $1.99, $490.6M dental impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue flat at $1.2B; constant currency organic revenue grew 7% YoY.","GAAP loss per share ($3.15) due to $490.6M dental impairment; adjusted EPS $1.99.","Dental segment impairment charge of $490.6M recorded in the quarter.","Fiscal 2023 second quarter ended September 30, 2022 results announced November 9, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2357008000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356600,"accession_number":"0001757898-22-000016","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q1 FY2023 revenue up 19% to $1.2B; adjusted EPS $1.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.2B, up 19% YoY; constant currency organic revenue up 6%.","Reported EPS of $1.10; adjusted EPS of $1.90 for the quarter.","Company updated fiscal 2023 outlook; guidance revision not detailed in release."],"consensus_eps_estimate":null,"consensus_eps_actual":1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":1156491000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356599,"accession_number":"0001193125-22-206687","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2022-07-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"STERIS shareholders re-elect all nine directors; say-on-pay approved at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; Jacqueline B. Kosecoff received 50.3M for, 36.9M against.","Ratification of Ernst & Young LLP as auditor for FY2023 passed with 82.5M for, 7.9M against.","Appointment of Ernst & Young Chartered Accountants as statutory auditor approved (82.7M for).","Advisory vote on executive compensation passed with 83.5M for, 3.7M against.","Quorum of 90.5M shares (90.48% outstanding) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375037,"accession_number":"0001757898-22-000008","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q4 revenue up 39% to $1.2B; adj. EPS $2.04; provides FY23 outlook","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 revenue $1.2B, up 39% as reported from $873.5M; constant currency organic growth 11%.","As reported EPS $0.52; adjusted EPS $2.04 for the quarter.","Company provides fiscal 2023 outlook, but specific guidance not included in excerpt.","Full-year fiscal 2022 results mentioned but details not available in provided text."],"consensus_eps_estimate":null,"consensus_eps_actual":2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":4585064000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393440,"accession_number":"0001757898-22-000004","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q3 FY2022 revenue $1.2B (+49% as reported); adjusted EPS $2.12; FY22 outlook raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.2B (+49% as reported; +9% constant currency organic) vs $808.9M in Q3 FY2021","Reported EPS $1.42; adjusted EPS $2.12 for the quarter","Fiscal 2022 full-year outlook raised (no specific figures provided in filing excerpt)"],"consensus_eps_estimate":null,"consensus_eps_actual":1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":3374378000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393439,"accession_number":"0001193125-22-001003","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2022-01-04T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"STERIS closes sale of Renal Care business to Evoqua Water Technologies for $196M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of Renal Care business to Evoqua Water Technologies on Jan 3, 2022 for ~$196M cash.","Proceeds will be used to pay down bank debt.","Renal Care was acquired as part of the Cantel Medical transaction (June 2021).","Business was primarily integrated into STERIS's Healthcare segment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411954,"accession_number":"0001193125-21-361726","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2021-12-20T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"STERIS to sell Renal Care business to Evoqua Water Technologies for ~$196M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration of approximately $196 million, subject to customary working capital and other adjustments.","Transaction expected to close in Q1 2022, subject to regulatory review and customary closing conditions.","Proceeds to be used to pay down debt.","Renal Care business was acquired as part of the Cantel Medical transaction in June 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411953,"accession_number":"0001757898-21-000030","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q2 FY2022 revenue $1.197B (+58% as reported); adj. EPS $1.99","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.197B, +58% as reported vs $756M prior year; constant currency organic growth +12%.","GAAP EPS $0.69; adjusted EPS $1.99. Company reiterates fiscal 2022 outlook.","Revenue increase reflects Cantel acquisition contribution and organic growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":2165407000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430688,"accession_number":"0001757898-21-000026","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STERIS Q1 revenue rises 45% to $968.4M; raises outlook and dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $968.4M, up 45% as reported vs. $668.9M in Q1 FY21; constant currency organic revenue up 21%.","Cantel Medical integration on track; company increases full-year outlook (specific targets not disclosed in snippet).","Quarterly dividend raised (amount not specified in press release excerpt).","First-quarter results reflect strong demand across healthcare and life sciences segments."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":968422000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430687,"accession_number":"0001193125-21-233329","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K","filed_at":"2021-08-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"STERIS shareholders re-elect all 9 director nominees and approve auditor at 2021 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 9 director nominees re-elected; Dr. Jacqueline B. Kosecoff received lowest support (58.2M for, 14.8M against).","Ratification of Ernst & Young LLP as auditor for FY2022 approved (68.0M for, 3.9M against).","Appointment of Ernst & Young Chartered Accountants as statutory auditor approved (68.0M for, 3.9M against).","Non-binding advisory vote on executive compensation approved (70.4M for, 2.5M against).","Quorum of 75.7M shares (88.63% outstanding) present at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430686,"accession_number":"0001193125-21-233344","cik":1757898,"company_name":"STERIS plc","ticker":"STE","form_type":"8-K/A","filed_at":"2021-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"STERIS plc appoints Paul E. Martin to two board committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul E. Martin appointed to Compliance and Technology Committee on July 29, 2021.","Also appointed to Compensation and Organization Development Committee same date.","Board size increased from ten to eleven on May 5, 2021 when Martin joined as director.","No other changes from original 8-K filed May 11, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":21115551286.739326,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}